Deans' stroke musings: Association between systemic immune-inflammation index at admission and post-stroke depression in patients with acute ischemic stroke

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, January 4, 2026

Association between systemic immune-inflammation index at admission and post-stroke depression in patients with acute ischemic stroke

Don't you know associations DO NOTHING FOR SURVIVOR RECOVERY!

Stroke research is to get survivors recovered, this did nothing towards that. You're fired!

Let's check how long you've known of the problem AND DID NOTHING TO SOLVE IT!

33% survivor depression (44 posts to May 2016)

Association between systemic immune-inflammation index at admission and post-stroke depression in patients with acute ischemic stroke

Jueyu Zhao

Xin Li^*

Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China

Background: Post-stroke depression (PSD) is one of the most common neuropsychiatric complications among stroke survivors, with a substantial impact on functional recovery and quality of life. This study aimed to investigate the association between the systemic immune-inflammation index (SII) at admission and the occurrence of PSD in patients with acute ischemic stroke (AIS).

Methods: We prospectively enrolled 318 consecutive patients with first-ever AIS admitted to our hospital between August 2024 and March 2025. Venous blood samples were collected at admission, and SII was calculated as neutrophil count × platelet count/lymphocyte count. At 3 months post-stroke, depressive symptoms were assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). Patients with a HAMD-17 score >7 were diagnosed with PSD and categorized accordingly into PSD and non-PSD groups.

Results: At the 3-month follow-up, 98 patients (30.82%) were diagnosed with PSD. Compared with the non-PSD group, patients in the PSD group had significantly higher SII values [658.66 (468.73–958.90) vs. 476.71 (362.73–646.83), p < 0.001]. In multivariate logistic regression analysis, after adjusting for potential confounders, patients in the highest SII tertile had a significantly increased risk of developing PSD compared with those in the lowest tertile (OR = 3.502, 95% CI: 1.582–7.752, p = 0.002). Receiver operating characteristic (ROC) curve analysis identified an optimal SII cut-off value of 602.503 for predicting PSD, with a sensitivity of 0.582, a specificity of 0.700, and an area under the curve (AUC) of 0.659 (95% CI: 0.592–0.726, p < 0.001).

Conclusion: Elevated SII levels at admission are positively associated with the development of PSD in AIS patients, suggesting that SII may serve as a valuable inflammatory biomarker for early identification of patients at high risk for PSD.